Research & Development

The European Microbiome Innovation for Health (EMIH) association and the Microbiome Therapeutics Innovation Group (MTIG) have announced a new collaborative agreement. The agreement seeks to advance microbiome drug development by improving collaboration between the two microbiome focused coalitions. Goals include facilitating discussions and synergies between international regulators and organising cross-continental meetings between member companies to gain wider perspectives on microbiome drug development. The agreement now brings together over 30 microbiome focused organisations covering both the public and private sectors.

“MTIG’s founding principal is to accelerate patients’ access to innovative microbiome therapeutics through our communal efforts,” commented Dr Nikole Kimes, chairman of MTIG and CEO of Siolta Therapeutics. “The EMIH represents innovative microbiome companies aligned with this core mission, and we look forward to sharing insights with one another to amplify our collective voice and transform the lives of patients on both sides of the Atlantic.”

Hervé Affagard, president of EMIH and CEO and co-founder of MaaT Pharma added, “As leading associations in the microbiome field, we understand that our strength lies in collaboration. By joining forces with MTIG, we will accelerate the development and deliver y of microbiome therapies, ensuring that ground-breaking treatments reach those who need them most, swiftly and safely. This partnership embodies our shared commitment to harmonising regulatory frameworks, and we look forward to working closely with MTIG.”